Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Expands By 139.4%

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totaling 150,485 shares, a growth of 139.4% from the June 30th total of 62,850 shares. Based on an average daily volume of 266,107 shares, the days-to-cover ratio is currently 0.6 days. Approximately 4.4% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GOVX. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a report on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, GeoVax Labs has a consensus rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Price Performance

GOVX opened at $0.72 on Tuesday. The firm has a market capitalization of $2.49 million, a PE ratio of -0.04 and a beta of 3.68. GeoVax Labs has a fifty-two week low of $0.69 and a fifty-two week high of $20.62. The company’s 50-day moving average is $1.52 and its 200 day moving average is $1.83.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.16) by $1.19. As a group, analysts expect that GeoVax Labs will post -8.69 EPS for the current year.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in GeoVax Labs during the first quarter valued at about $27,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at $253,000. Renaissance Technologies LLC purchased a new stake in GeoVax Labs during the 4th quarter worth about $104,000. Finally, HRT Financial LP purchased a new stake in GeoVax Labs during the 4th quarter worth about $31,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.